# Trump close to deal to allow Medicare coverage of weight loss drugs - Axios

## Metadata
| Field | Value |
|-------|-------|
| Source | Axios |
| URL | https://news.google.com/rss/articles/CBMifEFVX3lxTE9kUWROZHlKUG9PTUxSS0VrRnZuc1puU0FvQUtpaUJmVk5TaUtlY1VtNEV0dmtwY1dCVjJDOW9pTEpxWW5meFFLcVhubzNGMUZpMlR2NTlfS3VqOTZ3NnA4aDEzeTl1Z2FNemx3OG1QVjFmN3JXblI2SDJRN2Y?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-30 12:05 |
| Category | GLP-1|Policy|Regulatory |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Potential Medicare coverage of weight loss drugs could dramatically expand market access for GLP-1 medications like Ozempic and Wegovy, representing a significant policy shift with major market implications for obesity treatment startups.

## Key Entities
Trump Administration, Medicare, Novo Nordisk, Eli Lilly

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1|policy|regulatory #auto-scraped
